A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Sponsor
Hoffmann-La Roche
Study ID
NCT01181609
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab [Avastin] — DRUG
    5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen

Study Details

This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum. The anticipated time of study treatment is until disease progression.

Key Dates

First listed
Aug 13, 2010
Start date
Jun 30, 2005
Status verified
Jul 2014
Primary completion
May 31, 2010
Completion
May 31, 2010

Study Design

Enrollment
54 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Percentage of Participants Achieving Overall Disease Control (ODC) [ Time Frame: Baseline, after every other cycle to disease progression or death (Maximum of 52.5 months follow-up) ]

Related Studies